Presentation is loading. Please wait.

Presentation is loading. Please wait.

Unexplained Anaemia Acute Medicine Update Dr.Srinivasan Narayanan Consultant in Haematology University Hospital Southampton NHSFT.

Similar presentations


Presentation on theme: "Unexplained Anaemia Acute Medicine Update Dr.Srinivasan Narayanan Consultant in Haematology University Hospital Southampton NHSFT."— Presentation transcript:

1 Unexplained Anaemia Acute Medicine Update Dr.Srinivasan Narayanan Consultant in Haematology University Hospital Southampton NHSFT

2 Introduction  Common causes  Rare causes  Unexplained causes ?Pathophysiology Investigations Treatment options  Summary

3 Common causes of Anaemia

4 Diagnosis

5

6

7 Anaemia of chronic disease Impaired erythropoietin production Blunted response of marrow to endogenous erythropoietin Impaired iron metabolism mediated by inflammatory cytokines and stimulates liver production of hepcidin Hepcidin reduces iron absorption and decrease iron release from macrophages Normocytic, hypochromic anaemia with low iron binding capacity, normal or high ferritin and increased marrow iron

8 Myelodysplasia  Most often in older age groups  Anaemia could be only presenting feature  Difficult to diagnose in early stages  Blood film may help  Bone marrow assessment is required to confirm the diagnosis  Epo<500 may respond to Epo injections

9 MDS

10

11 Rare causes  Inherited Haemoglobinopathy disorders eg.unstable Hb Enzyme and membrane disorders Congenital dyserythropoietic anaemias Sideroblastic anaemias  Acquired Aplastic anaemia Paroxysmal nocturnal haemoglobinuria

12 Diagnosis?

13 Sideroblastic anaemia  Inherited and acquired causes  Mutation of genes in haem biosynthesis  Most common – ALA synthase gene mutation  Characterized by ring sideroblasts  Accumulation in perinuclear mitochondria within erythroblasts due to impaired iron utilisation  Acquired – MDS, alcohol, lead toxicity

14 Ring sideroblasts

15

16 Congenital dyserythropoietic anaemias  Rare congenital anaemias, 3 major subtypes  Mild to moderate anaemia due to ineffective erythropoiesis  Secondary iron overload due to increased iron absorption  Characteristic bone marrow changes and EM appearances of the erythroblasts

17 CDA-II

18 Diagnosis

19 Paroxysmal nocturnal Haemoglobinuria  Rare disease  Acquired mutation of PIG-A gene  Defect in the production of GPI protein anchors which protects against complement destruction  Increased red cell destruction

20 Normal Hematopoietic Cells Membrane lipid bilayer Transmembrane protein CD55CD59 GPI anchors

21 PNH  Hemolytic screen  Flow cytometry  Bone marrow biopsy  Treatment: Anticoagulation Eculizumab – monoclonal antibody against C5 Bone marrow transplantation

22 Unexplained anaemia  Commonly mild anaemia (1-2 g/dl low)  Normocytic  Usually multifactorial

23 Is it common?

24 Prevalance of anaemia increases over 50, >20% at 85 years or older

25

26 Is it clinically relevant?

27  Retrospective cohort study of over patients  Age over 65 years undergoing non- cardiac surgery  3 groups: Hct 54  30 day mortality increase by 1.6% for every 1% change in Hct<39– Wu et al

28 Features of unexplained anaemia

29 Possible causes  Age related renal insufficiency pronounced decline in DM/HT  Chronic inflammation  Stem cell ageing Reduced regenerative capacity  Androgen insufficiency  Shortened red cell survival

30

31 Investigations  Blood film  Reticulocyte count  Ferritin, STR, Haematinics  Haemolytic screen  Thyroid function  Erythropoietin level  Bone marrow biopsy

32 Erythropoietin MW 30400Da Discovered by Miyake et al in 1977 LC 4 alpha helical bundle class 1 cytokine

33 Erythropoietin  Renally secreted glycopeptide which stimulates erythropoiesis  Normally rises with anaemia  Blunted response in chronic inflammatory conditions, cancer, RA  Helps in reducing/avoid blood transfusions

34 Biology  Epo stimulates erythropoiesis  Low oxygen supply increases the production of Epo  Produced by the interstitial cells in kidney

35  32 week randomised, double blinded crossover trial with placebo and Epoetin alpha in elderly - Agnihotri P et al  62 patients with chronic anaemia

36

37  Increase in Hb>2 g/dl  Improvement in QOL studies

38  Monitor blood pressure, risk of hypertension  Avoid in patients with recent MI/CVA  Maintain Hb g/l, aim lower Hb level in patients with thrombocytosis, ischaemic vascular disease.  Responds better after iron/folate replacement in deficient patients.

39 ICUS  New terminology coined for unexplained cytopenias, persists for at least 6 months  Hb<110 g/l, with no clear reason  Acknowledgement of diagnostic uncertainty  Does not meet the diagnostic criteria for MDS or other conditions  Recommend long term monitoring as it may progress to MDS  Suboptimal Epo production could be the cause

40 Summary  Consider occult bleed, Anaemia of chronic disease or low grade haemolysis before UA.  Polypharmacy, inadequate nutrition, alcohol abuse also have a negative impact on erythropoiesis.  Associated neutropenia, low platelets are suggestive of bone marrow disorders.

41 Any Questions?


Download ppt "Unexplained Anaemia Acute Medicine Update Dr.Srinivasan Narayanan Consultant in Haematology University Hospital Southampton NHSFT."

Similar presentations


Ads by Google